SLDB Solid Biosciences Inc

Solid Biosciences to Participate at Upcoming Investor Conferences

Solid Biosciences to Participate at Upcoming Investor Conferences

CHARLESTOWN, Mass., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences:

  • Jefferies Global Healthcare Conference in London

    Bo Cumbo, President and CEO, and Gabriel Brooks, MD, Chief Medical Officer, will participate in a fireside chat on Tuesday, November 18, 2025, at 11:00 a.m. GMT (6:00 a.m. ET).
  • Piper Sandler 37th Annual Healthcare Conference

    Mr. Cumbo and Dr. Brooks will participate in a fireside chat on Tuesday, December 2, 2025, at 11:30 a.m. ET.

Live webcasts of the Jefferies and Piper Sandler fireside chats will be available on the Events page of the Investors section of the Company website or by . Webcast replays will be archived for 30 days on the Events page.

Institutional investors interested in one-on-one meetings with management during the conferences may reach out to their Jefferies or Piper Sandler representatives.

About Solid Biosciences

Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including SGT-003 for Duchenne muscular dystrophy (Duchenne), SGT-212 for Friedreich’s ataxia (FA), SGT-501 for catecholaminergic polymorphic ventricular tachycardia (CPVT), SGT-601 for TNNT2-mediated dilated cardiomyopathy and additional fatal, genetic cardiac diseases. The Company is also focused on developing innovative libraries of genetic regulators and other enabling technologies with promising potential to significantly impact gene therapy delivery cross-industry. Solid is advancing its diverse pipeline and delivery platform in the pursuit of uniting experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted by Duchenne, Solid’s mission is to improve the daily lives of patients living with devastating rare diseases. For more information, please visit .

Solid Biosciences Investor Contact:

Nicole Anderson

Director, Investor Relations and Corporate Communications

Solid Biosciences Inc.

Media Contact:

Glenn Silver

FINN Partners



EN
11/11/2025

Underlying

SLDBSolid Biosciences Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Solid Biosciences Inc

 PRESS RELEASE
Free
SLDB Solid Bioscienc...

Solid Biosciences Provides Interim Positive Clinical Update on Phase 1...

Solid Biosciences Provides Interim Positive Clinical Update on Phase 1/2 INSPIRE DUCHENNE Trial - 40 participants have been dosed with SGT-003 in the INSPIRE DUCHENNE trial to date - - Robust microdystrophin expression with consistent mechanistic evidence of dystrophin associated protein complex (DAPC) restoration and improvements in muscle integrity, including stabilization and improvement in cardiac function (LVEF) observed after treatment with SGT-003 - - SGT-003 continued to demonstrate an encouraging safety profile and has been generally well tolerated in the 40 participants dosed as...

March 11, 2026 1 EN
 PRESS RELEASE
Free
SLDB Solid Bioscienc...

Solid Biosciences Announces Oversubscribed $240 Million Private Placem...

Solid Biosciences Announces Oversubscribed $240 Million Private Placement CHARLESTOWN, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors for an approximately $240 million private placement, before deducting placement agent fees and offering expenses, which is expected to close on or about March 9, 2026, subject to the satisfacti...

March 6, 2026 1 EN
 PRESS RELEASE
Free
SLDB Solid Bioscienc...

Solid Biosciences to Present at the 2026 Muscular Dystrophy Associatio...

Solid Biosciences to Present at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference CHARLESTOWN, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced presentations on SGT-003, its next-generation investigational gene therapy for Duchenne muscular dystrophy, and SGT-212, its dual-route investigational gene therapy for Friedreich’s ataxia (FA), at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Confe...

March 6, 2026 1 EN
 PRESS RELEASE
Free
SLDB Solid Bioscienc...

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule ...

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CHARLESTOWN, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 17,600 restricted stock units (“RSUs”) to one newly hired employee. The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the applicable employee’s c...

March 2, 2026 1 EN
 PRESS RELEASE
Free
SLDB Solid Bioscienc...

Solid Biosciences Announces Positive Feedback from Type C Meeting with...

Solid Biosciences Announces Positive Feedback from Type C Meeting with FDA for SGT-003 Gene Therapy for Duchenne Muscular Dystrophy - IMPACT DUCHENNE: Company aligned with FDA on Phase 3 randomized, double-blind, placebo-controlled trial design -- IMPACT DUCHENNE: Company anticipates first participant dosing in Q1 2026 - - Company plans for additional meetings with the FDA in 1H 2026 to align on a potential accelerated approval pathway for SGT-003 - - INSPIRE DUCHENNE: SGT-003 continues to be generally well tolerated with 36 participants dosed as of February 9, 2026, in Phase 1/2 trial - ...

February 9, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch